United States - English - NLM (National Library of Medicine)

avpak - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - torsemide tablet is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. torsemide tablets are indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. torsemide tablet is contraindicated in patients with known hypersensitivity to torsemide or to sulfonylureas. torsemide tablet is contraindicated in patients who are anuric.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 20 mg - torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily stokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with torsemide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines,  such as those of the national

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with torsemide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the nation

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 10 mg - torsemide tablets are indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. torsemide tablets are indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. torsemide is contraindicated in patients with known hypersensitivity to torsemide or to sulfonylureas. torsemide is contraindicated in patients who are anuric.

United States - English - NLM (National Library of Medicine)

american regent, inc. - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 10 mg in 1 ml - torsemide injection is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease.  use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure.  chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. torsemide injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. torsemide injection is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. torsemide injection is contraindicated in patients with known hypersensitivity to torsemide or to sulfonylureas. torsemide injection is contraindicated in patients who are anuric.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with torsemide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the n

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 20 mg - torsemide is indicated for the treatment of edema associated with heart failure, renal disease, or hepatic disease. torsemide is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with torsemide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressu

United States - English - NLM (National Library of Medicine)

avkare - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with torsemide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national

United States - English - NLM (National Library of Medicine)

american health packaging - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 20 mg - torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with torsemide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with torsemide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national